The list is short. A small group of drugs are narrow therapeutic index (NTI): the dose that works and the dose that harms sit close together, so blood levels get monitored to stay in the window. Warfarin, levothyroxine, lithium, digoxin, tacrolimus and the other transplant immunosuppressants, and the anti-seizure drugs (phenytoin, carbamazepine, valproate, lamotrigine) are the ones that matter 1. Statins, blood pressure pills, antidepressants, antibiotics are not.
The "80% to 125%" number you've heard is real but misread. That's the FDA's rule for ordinary generics: average exposure must land in that range 2. It's the population average, not your own tablet; approved generics usually sit within a few percent of the brand, harmless for an antibiotic. For warfarin, a 10% shift can move your INR half a unit, enough to tip a stable patient toward bleeding or clotting. NTI generics get a tighter bar, roughly 90% to 111% 3 — still wider than your doctor's dose steps.
The change is the threat, not the generic. Seizure-free epilepsy patients had breakthrough seizures after a generic substitution; levels were lower in 21 of 26 measured 4. Yet the tightest trial built to catch this couldn't: a worst-case lamotrigine switch stayed within 98–103% of brand, no seizure control lost 5. Among 15,829 thyroid patients, normal TSH ran 85% in switchers versus 83% in non-switchers 6. On average, switching is fine. But a few are pharmacokinetically sensitive, and learn it only when their levels move.
Know your pill, and notice when it changes.
A held generic does the job. Synthroid runs $50–100 a month against $4–15 for the same molecule; the brand just buys consistency the pricey way.
The reward is nothing happening. The TSH at your physical reads where it did last year. Your INR sits in range, refill after refill, with no out-of-range value that triggers a phone call. On these drugs the goal isn't improvement; it's the absence of disruption.
The fine print — when to skip it, and what people get wrong
"Generic means 25% less drug." No — that's the population average; the risk is the change between products, never weakness. "My doctor would tell me." Your doctor doesn't know; the swap happens silently at the pharmacy counter.
Only for the NTI list. Tracking manufacturers on statins, blood-pressure pills, SSRIs, or antibiotics buys nothing. And never skip doses waiting for the "right" tablet during a shortage — a different generic beats no medication 2.
- 1Donnelly M, et al. (2025). Narrow Therapeutic Index Drugs: FDA Experience, Views, and Operations. Clinical Pharmacology and Therapeutics. link
- 2FDA (2020). Setting and Implementing Standards for Narrow Therapeutic Index Drugs. link
- 3Yu LX, et al. (2025). Analysis on the Impact of U.S. FDA's Narrow Therapeutic Index Bioequivalence Criteria on Generic Drug Applications. The AAPS Journal. link
- 4Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS (2008). Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology. link
- 5Privitera MD, et al. (2016). Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Lancet Neurology. link
- 6Brito JP, et al. (2022). Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US Adults. JAMA Internal Medicine. link
დაკავშირებული სახელმძღვანელოში (5)
- — An annual medication review is the natural moment to check your narrow-margin drugs haven't quietly switched manufacturers.
- — Some of the same narrow-margin drugs — transplant meds, blood thinners — are the ones grapefruit pushes toward toxic.
- — Both are about getting drug levels right — here it's the manufacturer, there it's your genes.
- — If you do end up on levothyroxine, it's a narrow-therapeutic-index drug where consistency matters.
- — If the screen leads to levothyroxine, it's a narrow-therapeutic-index drug — staying on one manufacturer matters.
Brand vs Generic: When It Matters
Asking the pharmacy to dispense a consistent generic manufacturer is free. Insisting on brand-name (Synthroid ~$50–100/month vs. generic ~$4–15/month; brand AEDs 10–50× the generic) is where cost enters — but the default consistency move costs nothing.
Reading the imprint code and manufacturer name on the pharmacy label each refill, having a brief conversation with the pharmacist, and following up with TSH/INR/level rechecks after any unavoidable switch. Light but ongoing — every refill carries a small check.
For patients on a narrow-therapeutic-index drug, keeping the manufacturer consistent prevents the symptom destabilization (TSH excursions in hypothyroid patients, INR swings in warfarin patients, breakthrough seizures, tacrolimus trough drops) documented in Berg et al. 2008 (Neurology) and the AED switchback literature (Andermann 2007). The effect is conditional on being on one of these drugs — for the population at large, zero — but for the affected subgroup it is a meaningful, named, week-to-week stability gain.
The downstream stakes of unstable NTI dosing are concrete: stroke and major bleeding from INR excursions on warfarin, biopsy-proven acute rejection from tacrolimus trough drops (Lao et al. 2020), atrial fibrillation and accelerated bone loss from over-replaced levothyroxine, status epilepticus from breakthrough seizures. The Dentali 2011 systematic review found no excess events in pooled brand-vs-generic warfarin data, but conversion studies in transplant patients show increased rejection risk — the picture is conditional, not universal.
The mechanism (steep dose-response, narrow concentration window) is settled; the FDA's RSABE bioequivalence approach and the 95–105% potency specification for levothyroxine institutionalize it (Donnelly 2025; Yu 2025). But the controlled-trial evidence that switching matters clinically is contested: EQUIGEN (Privitera 2016, Berg 2017) found no signal for lamotrigine, Brito 2022 found no signal for generic-to-generic levothyroxine, Dentali 2011 found no signal for warfarin. The case-series literature (Berg 2008) and conversion-study tacrolimus data (Lao 2020) carry real signal. Strong evidence for the practice in transplant, mixed-to-weak for warfarin and levothyroxine.
Indirect — destabilized levothyroxine produces the fatigue/sluggishness of hypothyroid drift or the wired-but-tired of subclinical hyperthyroidism, and AED level changes affect daytime alertness. The effect is only felt when destabilization happens, not from the practice itself.
Indirect — AED level changes (especially carbamazepine, phenytoin, lamotrigine) shift cognitive performance, and TSH drift produces brain fog. Manufacturer consistency prevents these swings rather than producing focus gains in the affirmative sense.
Hypothyroid drift from levothyroxine destabilization produces low mood, irritability, and (at the extreme) depressive symptoms — the indirect mood cost of manufacturer instability when the substance is levothyroxine. Not present for the warfarin / AED / tacrolimus cases.